Metabolic reprograming confers tamoxifen resistance in breast cancer

Breast cancer is the most common cancer among females and the leading cause of cancer-related deaths. Approximately 70 % of breast cancers are estrogen receptor (ER) positive. An ER antagonist such as tamoxifen is used as adjuvant therapy in ER-positive patients. The major problem with endocrine the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chemico-biological interactions 2021-09, Vol.347, p.109602-109602, Article 109602
Hauptverfasser:	Mishra, Alok, Srivastava, Anshuman, Pateriya, Ankit, Tomar, Manendra Singh, Mishra, Anand Kumar, Shrivastava, Ashutosh
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Estrogen receptor Metabolism Tamoxifen Tamoxifen resistance
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!